Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior body weight reduction and glycemic control compared to semaglutide, insulin degludec, and insulin glargine in patients with type 2 diabetes.
For patients with Type 2 Diabetes struggling with weight and blood sugar, Tirzepatide offers a once-weekly injection that has been shown to be more effective than semaglutide, insulin degludec, and insulin glargine in reducing both body weight and HbA1c. Treatment starts at a low dose (2.5 mg) and is titrated up to 5, 10, or 15 mg weekly to manage side effects. This therapy is particularly beneficial for those who have not achieved targets with oral medications or other injectables.
In summary, TZP was greater to semaglutide in reducing HbA1c... TZP attained more pronounced HbA1c reductions at the end of the study competed to insulin glargine... TZP was superior to dulaglutide in GC and reduction of BW
Why this rating
Based on multiple large-scale, randomized, controlled Phase 3 clinical trials (SURPASS 1-6) with consistent results.
Source
Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
Salvatore Corrao et al. · Frontiers in Endocrinology · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →